Light Fix Trial at Vienna General Hospital Will Apply IlluminOss’ Minimally Invasive, Patient-Specific Bone Stabilization Technology
EAST PROVIDENCE, RI and VIENNA, AUSTRIA–(Marketwired – Mar 3, 2015) – IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that the first patient has been enrolled in its EU Light Fix trial for the treatment of impending and pathologic fractures in the humerus due to metastatic carcinoma. The trial will be led by Prof. Reinhard Windhager, MD of the University Clinic of Vienna Orthopaedic Department. Prof. Windhager is a world-leading orthopedic oncologist who heads the Department of Orthopaedic Surgery at Vienna General Hospital (AKH). The EU Light Fix trial will enroll up to 45 patients at approximately 10 centers in Austria, Germany and the Netherlands.
IlluminOss Medical is focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, the IlluminOss System. This minimally invasive technology allows for fracture fixation through revolutionary patient-specific intramedullary implants.
The IlluminOss System utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The simple, percutaneous surgical approach enables surgeons to create a patient-conforming implant. In many cases it allows the patient to get back to daily activities more quickly without the hindrance of a hard cast. Benefitsobserved from the use of the product in patients include smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates. The small diameter of the flexible catheter gives the surgeon greater freedom of surgical approach. Once cured, the implant
provides longitudinal strength and rotational stability over the length of the implant.
“The IlluminOss System will potentially allow orthopedic surgeons to approach impending and actual fractures resulting from metastatic malignancy in a groundbreaking way that will benefit both the surgeon and the patient,” said Prof. Windhager. “I am pleased to lead the first Light Fix trial in the EU and hope our efforts will help validate an approach to orthopedic surgery that can provide treatment options for patients that previously had little or no recourse and also potentially lessen complications and improve outcomes.”
“We are honored that Prof. Windhager and Vienna General Hospital have chosen to collaborate with IlluminOss Medical on this important trial for the repair and stabilization of impending and pathologic fractures in the humerus due to metastatic carcinoma,” said Robert Rabiner, president of IlluminOss Medical. “The University Clinic of Vienna Orthopaedic Department has a long tradition of providing the highest standards of patient care, and we believe its practices influence orthopedic treatment approaches throughout Austria and the surrounding European region. Together with our valued Austrian distributor, Cherry Med Medical Solutions, we expect the IlluminOss System will present a superior way to approach the repair of fractures resulting from metastatic carcinoma.”
Prof. Windhager has served as the president of the Austrian Society of Orthopaedic Surgery (ÖGO). He was also president of the International Society of Limb Salvage (ISOLS), which focuses on promoting research, education and clinical practice related to musculoskeletal tumors with the ultimate goal of improving patient care related to limb salvage interventions. He earned his doctorate in 1981 from the University of Innsbruck as a Doctor of Medicine and received training at the General Hospital Linz.
The first patient enrolled in the EU Light Fix trial is a female with metastatic cancer of the left humerus.
About General Hospital Of Vienna (AKH)
The General Hospital of Vienna has more than 300 years of history. Originally known as a “home for the poor and invalid”, it has developed into one of the most modern and advanced hospitals in Europe. With more than 30 university clinics and clinical institutes, AKH guarantees extremely high standards and innovative technologies in all medical fields. At the AKH, patient care, instruction and research have been laid down as inseparable and equal elements. The patient is always at the center of AKH’s tasks and objectives.
IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, the IlluminOss System. This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The system utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in international countries under a CE Mark for approved clinical applications through both a direct sales force and distribution networks.
Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology. Learn more at www.illuminoss.com.
The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.